Skip to Content
  • Title
    CEO
  • Affiliation
    Mylan
  • Age
    49

Mylan is still singed from the firestorm that erupted two years ago over price hikes to its EpiPen allergy shot. As pressure from President Trump and regulators has constrained drug pricing, Bresch is struggling to make money in the U.S.—particularly after cannibalizing Mylan’s own sales by launching a generic EpiPen. After a 20% drop in North American revenue in the first half of 2018, Mylan lowered its financial outlook for the year, and the board now says it’s exploring strategic options, which could include a merger.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Personal Information

Previous Rank23
Newcomer?-

Company Financials (2017, or most recently completed fiscal year)

Revenues ($M)11,907.7
Profits ($M)696
Market Value as of 09/18/18 ($M)
19,493.6